Aktuelle Neurologie 2013; 40(02): 96-100
DOI: 10.1055/s-0033-1333767
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Small Fiber Neuropathien

Small Fiber Neuropathies
N. Üçeyler
1   Neurologische Klinik, Universitätsklinikum Würzburg, Würzburg
,
C. Sommer
1   Neurologische Klinik, Universitätsklinikum Würzburg, Würzburg
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. März 2013 (online)

Zusammenfassung

Small fiber Neuropathien (SFN) sind eine Subgruppe der sensiblen Polyneuropathien, die ausschließlich bzw. ganz überwiegend dünn-bemarkte A-delta Fasern und unbemarkte C-Fasern betreffen. Das typische klinische Bild ist geprägt von akralen brennenden Schmerzen mit Par- und Dysästhesien. Die neurologische Untersuchung ergibt ebenso wie die elektrophysiologische Routinediagnostik normale bis allenfalls marginal pathologische Befunde. Nur funktionelle und morphologische Zusatzuntersuchungen können Störungen der small fiber Funktion bzw. Morphologie aufdecken. Die Ätiologie der SFN ist sehr vielseitig und die Patienten müssen bezüglich potenziell behandelbarer Ursachen untersucht werden. Die häufigste Ursache für eine SFN ist der Diabetes mellitus bzw. bereits eine gestörte Glukosetoleranz. Hinsichtlich der Pathophysiologie der Schmerzen gibt es Hinweise auf eine Sensibilisierung der Nozizeptoren und bei einer Subgruppe von Patienten kann eine hereditäre Natriumkanalerkrankung mit Mutation im Gen für den spannungsabhängigen Natriumkanal Nav1.7 vorliegen. Diese Erkenntnisse könnten künftig in die Entwicklung einer spezifischen analgetischen SFN-Therapie münden, die sich im Falle einer idiopathischen SFN derzeit noch an den generellen Leitlinien zur Behandlung neuropathischer Schmerzen generell orientiert.

Abstract

Small fibre neuropathies (SFN) are a subgroup of sensory neuropathies in which almost exclusively thinly myelinated A-delta fibres and unmyelinated C-fibres are affected. The typical clinical presentation consists in acral burning pain accompanied by par- and dysaesthesias. Neurological examination as well as standard neurophysiological assessment reveal normal to marginally pathological findings. Special investigation techniques are necessary to detect functional and morphological small fibre impairment. The aetiology of SFN is variable and the patients should be examined carefully with regard to underlying potentially treatable diseases. The most frequent reason for SFN is diabetes mellitus; SFN may also be associated with impaired glucose tolerance. Pain in SFN may be caused by sensitisation of peripheral nociceptors and in a subgroup of patients also by a hereditary sodium channel disease based on mutations in the gene of the voltage-gated sodium channel Nav1.7. These pathophysiological insights may lead to the development of specific SFN analgesics. At present, treatment of idiopathic SFN follows guidelines on the treatment of neuropathic pain in general.

 
  • Literatur

  • 1 Devigili G, Tugnoli V, Penza P et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 2008; 131: 1912-1925
  • 2 Lacomis D. Small-fiber neuropathy. Muscle Nerve 2002; 26: 173-188
  • 3 Stewart JD, Low PA, Fealey RD. Distal small fiber neuropathy: results of tests of sweating and autonomic cardiovascular reflexes. Muscle Nerve 1992; 15: 661-665
  • 4 Lumpkin EA, Caterina MJ. Mechanisms of sensory transduction in the skin. Nature 2007; 445: 858-865
  • 5 Lefaucheur JP, Creange A. Neurophysiological testing correlates with clinical examination according to fibre type involvement and severity in sensory neuropathy. J Neurol Neurosurg Psychiatry 2004; 75: 417-422
  • 6 Sommer C, Richter H, Rogausch JP et al. A modified score to identify and discriminate neuropathic pain: a study on the German version of the Neuropathic Pain Symptom Inventory (NPSI). BMC Neurol 2011; 11: 104
  • 7 Bouhassira D, Attal N, Fermanian J et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004; 108: 248-257
  • 8 Rolke R, Baron R, Maier C et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 2006; 123: 231-243
  • 9 Magerl W, Krumova EK, Baron R et al. Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. Pain 2010; 151: 598-605
  • 10 Scherens A, Maier C, Haussleiter IS et al. Painful or painless lower limb dysesthesias are highly predictive of peripheral neuropathy: comparison of different diagnostic modalities. Eur J Pain 2009; 13: 711-718
  • 11 Kennedy WR, Wendelschafer-Crabb G, Walk D. Use of skin biopsy and skin blister in neurologic practice. J Clin Neuromuscul Dis 2000; 1: 196-204
  • 12 Hovaguimian A, Gibbons CH. Diagnosis and treatment of pain in small-fiber neuropathy. Curr Pain Headache Rep 2011; 15: 193-200
  • 13 Agostino R, Cruccu G, Romaniello A et al. Dysfunction of small myelinated afferents in diabetic polyneuropathy, as assessed by laser evoked potentials. Clin Neurophysiol 2000; 111: 270-276
  • 14 Jamal GA, Hansen S, Weir AI et al. Cerebral cortical potentials to pure non-painful temperature stimulation: an objective technique for the assessment of small fibre pathway in man. J Neurol Neurosurg Psychiatry 1989; 52: 99-105
  • 15 Kaube H, Katsarava Z, Kaufer T et al. A new method to increase nociception specificity of the human blink reflex. Clin Neurophysiol 2000; 111: 413-416
  • 16 Ochoa J, Torebjork HE, Culp WJ et al. Abnormal spontaneous activity in single sensory nerve fibers in humans. Muscle Nerve 1982; 5: S74-S77
  • 17 Kennedy WR, Nolano M, Wendelschafer-Crabb G et al. A skin blister method to study epidermal nerves in peripheral nerve disease. Muscle Nerve 1999; 22: 360-371
  • 18 Tavakoli M, Marshall A, Banka S et al. Corneal confocal microscopy detects small-fiber neuropathy in Charcot-Marie-Tooth disease type 1A patients. Muscle Nerve 2012; 46: 698-704
  • 19 Sumner CJ, Sheth S, Griffin JW et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108-111
  • 20 Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001; 24: 1448-1553
  • 21 Hoitsma E, Marziniak M, Faber CG et al. Small fibre neuropathy in sarcoidosis. Lancet 2002; 359: 2085-2086
  • 22 Üçeyler N, Sommer C. M Fabry: Diagnose und Therapie. Schmerz 2012; 26: 609-619
  • 23 Üçeyler N, Kafke W, Riediger N et al. Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology 2010; 74: 1806-1813
  • 24 Orstavik K, Jorum E. Microneurographic findings of relevance to pain in patients with erythromelalgia and patients with diabetic neuropathy. Neurosci Lett 2010; 470: 180-184
  • 25 Faber CG, Hoeijmakers JG, Ahn HS et al. Gain of function Nav1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol 2012; 71: 26-39
  • 26 Dib-Hajj SD, Cummins TR, Black JA et al. Sodium channels in normal and pathological pain. Annu Rev Neurosci 2010; 33: 325-347
  • 27 Dib-Hajj SD, Rush AM, Cummins TR et al. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 2005; 128: 1847-1854
  • 28 Hoeijmakers J, Merkies I, Gerrits M et al. Genetic aspects of sodium channelopathy in small fiber neuropathy. Clin Genet 2012; 82: 351-358
  • 29 Dabby R, Gilad R, Sadeh M et al. Acute steroid responsive small-fiber sensory neuropathy: a new entity?. J Peripher Nerv Syst 2006; 11: 47-52
  • 30 Ho TW, Backonja M, Ma J et al. Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies. Pain 2009; 141: 19-24
  • 31 Baron R, Binder A, Birklein F et al. Pharmakologische nicht-interventionelle Therapie chronischer neuropathischer Schmerzen. In: Diener HC, Weimar C. Hrsg Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme; 2012: 771-783
  • 32 Attal N, Cruccu G, Baron R et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010 17. 1113-e88
  • 33 Webster LR, Peppin JF, Murphy FT et al. Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. Diabetes Res Clin Pract 2011; 93: 187-197